We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Loss of Ron Signaling Linked to Development of Inflammatory Bowel Disease

By LabMedica International staff writers
Posted on 14 May 2014
Cancer researchers have found that decreased molecular signaling by the Ron receptor tyrosine kinase (macrophage-stimulating protein receptor) is linked to the development of inflammatory bowel disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications.

The Ron receptor tyrosine kinase, a member of the MET proto-oncogene family, is a pathogenic factor implicated in tumor malignancy. More...
Specifically, aberrations in Ron signaling result in increased cancer cell growth, survival, invasion, angiogenesis, and drug resistance. Biochemical events such as ligand binding, receptor overexpression, generation of structure-defected variants, and point mutations in the kinase domain contribute to Ron signaling activation.

Investigators at the University of Cincinnati (Ohio, USA) have now found that decreased Ron signaling is linked to the development of IBD. This data was obtained from experiments conducted with a line of mice that had been genetically engineered to lack the tyrosine kinase signaling domain of Ron (TK-/- mice). These animals and wild-type controls were utilized as a well-characterized model of chronic colitis induced by cyclic exposure to dextran sulfate sodium.

Results reported in the April 17, 2014, online edition of the American Journal of Physiology-Gastrointestinal and Liver Physiology revealed that TK-/- mice were more susceptible to injury as judged by increased mortality compared to control mice and developed more severe colitis. In addition, loss of Ron led to significantly reduced body weights and more aggressive clinical histopathologies. Ron loss also resulted in a dramatic reduction in colonic epithelial cell proliferation and increased proinflammatory cytokine production, which was associated with alterations in important signaling pathways known to regulate IBD.

"Genome-wide linkage studies have identified the Ron receptor tyrosine kinase and its hepatocyte growth factor-like protein (HGFL) as genes highly associated with IBD,” said senior author Dr. Susan Waltz, professor in of cancer biology at the University of Cincinnati. "However, only scant information exists on the role of Ron or HGFL in IBD. Based on the linkage of Ron to IBD, we examined the biological role of Ron in colitis.”

"We found that genetic loss of Ron led to aggressive inflammation and damage to the colon of models with IBD,” said Dr. Waltz. "In addition, there are a number of small changes called single nucleotide polymorphisms (SNP) in humans which map to both the Ron and HGFL gene and have been identified to strongly associate IBD disease in humans. Our studies suggest that these SNPs may reduce the function of Ron and HGFL leading to chronic intestinal inflammation and damage. With the knowledge that we have gained in studying these proteins in cancer biology, we hope this information may be translated to help patients with Crohn’s disease and ulcerative colitis. Further studies on the Ron signaling pathway are needed and could reveal an important new target for these conditions."

Related Links:

University of Cincinnati



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.